Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.37 |
| ▸ | OTC | P00480 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL6535144 | 1.00 | PRCP (0.37) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL6534744 | 1.00 | PRCP (0.37) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL22205220 | 1.00 | PRCP (0.37) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL28901147 | 1.00 | PRCP (0.37) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL11905364 | 0.96 | PRCP (0.40) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL4807560 | 0.96 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL3087368 | 0.96 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL1417757 | 0.96 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL8697426 | 0.96 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL28774540 | 0.96 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170333517-A1 | COMPOSITIONS AND METHODS FOR INHIBITING FIBROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-23 | — | — | US | claimed |
| WO-2016077365-A1 | COMPOSITIONS AND METHODS FOR INHIBITING FIBROSIS | THE UAB RESEARCH FOUNDATION (US) | 2016-05-19 | — | — | WO | claimed |
| CN-111808011-B | High penetration composition and its application | 泰飞尔生物医药(苏州)有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230228734-A1 | METHOD FOR FIBRINOGEN MEASUREMENT | A&T CORPORATION (JP) | 2023-07-20 | — | — | US | disclosed |
| US-20220120768-A1 | REAGENT FOR MEASURING FIBRINOGEN | A&T CORPORATION (JP) | 2022-04-21 | — | — | US | disclosed |
| CN-113636965-A | High penetration composition and application thereof | 于崇曦 | 2021-11-12 | — | — | CN | disclosed |
| CN-107320732-B | High penetration composition and application thereof | 于崇曦 | 2021-09-07 | — | — | CN | disclosed |
| CN-108191846-B | High penetration composition and application thereof | 于崇曦 | 2021-08-20 | — | — | CN | disclosed |
| CN-111808011-A | High penetration composition and application thereof | 于崇曦 | 2020-10-23 | — | — | CN | disclosed |
| WO-2020116556-A1 | REAGENT FOR MEASURING FIBRINOGEN | 株式会社エイアンドティー | 2020-06-11 | — | — | WO | disclosed |
| US-10335448-B2 | Compositions and methods for inhibiting fibrosis | THE UAB RESEARCH FOUNDATION (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170333517-A1 | COMPOSITIONS AND METHODS FOR INHIBITING FIBROSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-23 | — | — | US | disclosed |
| US-8945825-B2 | Homogeneous activity test for determining enzymatic reactions | SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2395354-A1 | Homogenous activity test for determining enzymatic reactions | Siemens Healthcare Diagnostics Products GmbH (DE) | 2011-12-14 | — | — | EP | disclosed |
| EP-2395355-A1 | Homogenous activity test for determining enzymatic reactions | Siemens Healthcare Diagnostics Products GmbH (DE) | 2011-12-14 | — | — | EP | disclosed |
| US-20100094020-A1 | POLYCATIONIZED PHOSPHOLIPID DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094020-A1 | POLYCATIONIZED PHOSPHOLIPID DERIVATIVES | PHOSPHO1, PLTP, PTDSS2 | PRCP 1198/4885OTC 3527/4885NOS2 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.